Cangrelor: An emerging therapeutic option for patients with coronary artery disease

Current Medical Research and Opinion

Volumn 30, Issue 5, 2014, Pages 813-828

  Kubica, Jacek ^a   Kozinski, Marek ^a   Navarese, Eliano Pio ^a   Tantry, Udaya ^b   Kubica, Aldona ^a   Siller Matula, Jolanta Maria ^c   Jeong, Young Hoon ^d   Fabiszak, Tomasz ^a   Andruszkiewicz, Anna ^a   Gurbel, Paul Alfred ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Gyeongsang National University   (South Korea)

Author keywords

Antiplatelet therapy; AR C69931MX; Cangrelor; P2Y12 inhibitor

Indexed keywords

CANGRELOR; CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSPNEA; HEART INFARCTION; HUMAN; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SURGICAL PATIENT; SYSTEMATIC REVIEW;

ADENOSINE MONOPHOSPHATE; ANIMALS; CORONARY ARTERY DISEASE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899092192     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.880050     Document Type: Review

References (89)

1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
3. Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: A meta-analysis of randomized trials. QJM 2011;104:561-9
4. Storey RF, Sanderson HM, White AE, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000;110:925-34
5. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 2006;103:11069-74
6. Algaier I, Jakubowski JA, Asai F, von Kügelgen I. Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor. J Thromb Haemost 2008;6:1908-14
7. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010;121:171-9
8. Navarese EP, Buffon A, Kozinski M, et al. A critical overview on ticagrelor in acute coronary syndromes. QJM. 2013;106:105-15
9. Grzesk G, Kozinski M, Navarese EP, et al. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thromb Res 2012;130:65-9
10. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009;361:2330-41
11. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009;361:2318-29
12. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303-13
13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009;151:264-9
14. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55
15. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4
16. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 2008;122:776-81
17. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation. Eur Heart J 2011;32:2999-3054
18. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619
19. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segmentelevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804
20. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013;61:1601-6
21. Cappell MS. Intestinal (mesenteric) vasculopathy. II. Ischemic colitis and chronic mesenteric ischemia. Gastroenterol Clin North Am 1998;27:827-60
22. Bassiouny HS. Nonocclusive mesenteric ischemia. Surg Clin North Am 1997;77:319-26
23. Catto-Smith AG, Hardin JA, Patrick MK, et al. The effect of atrial natriuretic peptide on intestinal electrolyte transport. Regul Pept 1991;36:29-44
24. Scott RB, Maric M. The effect of atrial natriuretic peptide on small intestinal contractility and transit. Peptides 1991;12:799-803
25. Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93:229-37
26. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6:54-61
27. Dörler J, Edlinger M, Alber HF, et al. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011;32:2954-61
28. Koul S, Smith JG, Schersté n F, et al. Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2011;32:2989-97
29. Steinhubl SR, Berger PB, Brennan DM, Topol EJ. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-43
30. Szük T, Gyöngyösi M, Homorodi N, et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 2007;153:289-95
31. Widimsky P, MotovskáZ, Simek S, et al. Clopidogrel pretreatment in stable angina: For all patients46 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? Eur Heart J 2008;29:1495-503
32. Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: Results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010;56:550-7
33. Agrawal K, Bhatt DL. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol 2013;10:121-2
34. SoučkováL, OpatřilováR, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol 2013;69:309-17
35. Fuller EE, Alemu R, Harper JF, Feldman M. Relation of nausea and vomiting in acute myocardial infarction to location of the infarct. Am J Cardiol 2009;104:1638-40
36. Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J 2012;163:768-76
37. Frelinger 3rd AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013;61:872-9
38. Bouman HJ, van Werkum JW, Hackeng CM, et al. Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel- pretreated subjects. Neth Heart J 2009;17:195-8
39. Tantry US, Jeong YH, Navarese EP, et al. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther 2013;11:447-62
40. Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011;22:579-87
41. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-73
42. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51
43. Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study. J Thromb Haemost 2012;10:529-42
44. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-5
45. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-17
46. Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-66
47. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84
48. Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: Risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012;60:388-96
49. Kubica J, Koziński M, Navarese EP, et al. Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized clinical trials. Cardiol J 2012;19:230-42
50. Kubica A, Kozinski M, Navarese EP, et al. Intracoronary versus intravenous abciximab administration in STEMI patients: Overview of current status and open questions. Curr Med Res Opin 2011;27:2133-44
51. Navarese EP, Kozinski M, Obonska K, et al. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: A meta-analysis of randomized trials. Platelets 2012;23:274-81
52. Ingall AH, Dixon J, Bailey A, et al. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy. J Med Chem 1999;42:213-20
53. Greenbaum AB, Grines CL, Bittl JA, et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- And active-controlled trial. Am Heart J 2006;151:689.e1-10
54. Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: A review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 2009;7:1195-201
55. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001;85:401-7
56. Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther 2010;8:1069-77
57. Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008;121:527-34
58. Srinivasan S, Mir F, Huang JS, et al. The P2Y12 antagonists, 2-methylthioadenosine 50-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem 2009;284:16108-17
59. Xiang B, Zhang G, Ren H, et al. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One 2012;7:e51037
60. Ferreiro JL, Ueno M, Tello-Montoliu A, et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: An in vitro pharmacodynamic investigation. J Thromb Thrombolysis 2013;35:155-64
61. Yang XM, Liu Y, Cui L, et al. Platelet P2Y12 blockers confer direct postconditioning- like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 2013;18:251-62
62. Yang XM, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther 2013;27:109-15
63. Jacobsson F, Swahn E, Wallentin L, et al. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin Ther 2002;24:752-65
64. Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010;50:27-35
65. Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007;154:702-9
66. Ravnefjord A, Weilitz J, Emanuelsson BM, et al. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res 2012;130:622-8
67. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and ARC69931MX in patients with ischaemic heart disease. Platelets 2002;13:407-13
68. Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6:1153-9
69. Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011;105(Suppl 1):S75-81
70. Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010;159:502-17
71. Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012;34:44-55
72. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012;163:182-90
73. Leonardi S, Truffa AA, Neely ML, et al. A novel approach to systematically implement the universal definition of myocardial infarction: Insights from the CHAMPION PLATFORM trial. Heart 2013;99:1282-7
74. Serebruany VL, Pokov AN, Fortmann SD, Dinicolantonio JJ. Disbalance between mortality and non-fatal vascular events in the CHAMPIONPHOENIX trial: The cangrelor efficacy challenge. Thromb Haemost 2013: Published online 28 Nov 2013, doi: 10.1160/TH13-08-0631
75. Gé né reux P, Stone GW, Harrington RA, et al. Impact of intra-procedural stent thrombosis during percutaneous coronary intervention: Insights from the CHAMPION PHOENIX Trial. J Am Coll Cardiol 2013: Published online 24 Oct 2013, doi: 10.1016/j.jacc.2013.10.022
76. Lange RA, Hillis LD. The duel between dual antiplatelet therapies. N Engl J Med 2013;368:1356-7
77. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet 2013;382:1981-92
78. Serebruany VL, Aradi D, Kim MH, et al. Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials. Int J Cardiol 2013;169:225-8
79. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial. JAMA 2012;307:265-74
80. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-4
81. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-5
82. Serebruany V, Pokov I, Kuliczkowski W, et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008;100:76-82
83. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011;123:798-813
84. Angiolillo DJ, Capranzano P, Desai B, et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009;124:318-22
85. Kozinski M, Pstragowski K, Kubica JM, et al. ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-ofhospital cardiac arrest survivors improves clinical outcomes: The first European experience. Scand J Trauma Resusc Emerg Med 2013;21:22
86. Krajewski S, Kurz J, Neumann B, et al. Short-acting P2Y12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia. Br J Anaesth 2012;108:912-21
87. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945-53
88. Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost 2012;108:1031-6
89. Balduini A, Di Buduo CA, Malara A, et al. Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes. Haematologica 2012;97:1657-65.